Program Overview
Rabies remains a vaccine-preventable disease that is almost invariably fatal after clinical onset. Regional elimination depends on interrupting transmission in dog populations and improving access to practical immunization tools—not only on individual post-exposure care.
Orion Biotech is developing a next-generation rabies vaccine centered on prefusion-stabilized rabies virus glycoprotein (RABV-G). The program builds on established recombinant antigen design, adjuvant-enhanced immunogenicity, and a validated two-dose schedule that compares favorably with the four- to five-dose regimens common in current practice.
Development Direction
The long-term goal is a one-dose candidate that can deliver effective immunity during a single field contact—supporting high-coverage dog vaccination campaigns and, separately, simplified pre-exposure protection for high-risk populations. This aligns with global public-health strategies to end human deaths from dog-mediated rabies.
Orion Biotech does not position a one-dose product as a replacement for standard post-exposure prophylaxis in unvaccinated exposed individuals. Claims remain stage-appropriate and evidence-bound.
Evidence & Outlook
Key development readouts include rapid neutralizing antibody induction, durability, challenge protection, and practical advantages in stability and scalable manufacturing. The team brings publication and patent experience in rabies vaccinology.
We welcome discussions with public-health agencies, veterinary partners, CDMOs, and research institutions aligned with responsible regional elimination goals.